Pep-Talk
MK-677 vial

MK-677

Educational resource. Not medical advice. No dosing or instructions.

Safety grade
5/10
Moderate
Also known as
ibutamorenmk677mk 677l-163,191l163191mk 0677mk-0677mk-677oratrope
AA sequence
Not available yet.
What it is
MK-677 (ibutamoren) is an investigational, oral ghrelin-receptor agonist that increases growth hormone and IGF-1 signaling. It is not approved as a general wellness compound.
Why people discuss it
It’s commonly discussed for appetite, sleep/recovery feelings, and body-composition goals. Practical downsides frequently center on appetite/weight gain, fluid retention, and glucose tolerance.

Why people are interested in this peptide and how it is commonly discussed in real-world wellness, rehabilitation, and athletic communities.

Why people are interested
  • a bioactive compound discussed in research and/or clinical contexts
  • this entry summarizes what it is, what it is studied for, and key evidence limitations without providing protocols
  • sleep quality support
  • falling asleep more easily (anecdotal)
  • staying asleep through the night (anecdotal)
  • circadian rhythm support
  • next-day recovery and readiness support

MK-677 (ibutamoren) is an investigational oral ghrelin-receptor agonist that increases growth hormone/IGF-1 signaling. It’s often discussed for sleep, appetite, and body-composition goals, but tradeoffs commonly involve appetite/weight gain, fluid retention, and glucose tolerance concerns.

Common reasons people consider it

  • Increases GH/IGF-1 signaling in studies (mechanistic effect)
  • Often discussed for sleep quality or recovery feelings (mixed reports)
  • Often discussed for appetite and weight gain (common effect)

Most commonly reported downsides

  • Increased appetite / cravings
  • Water retention or puffiness
  • Fatigue or lethargy
  • Numbness/tingling or carpal-tunnel-like complaints (reports vary)
  • Vivid dreams (reports vary)

Rare but important symptoms to watch for

These are uncommon, but if they occur, stop and seek medical care.

  • Worsening blood sugar control signs (excess thirst/urination, blurry vision)
  • Rapid swelling, shortness of breath, or chest pain
  • Severe headaches or neurologic symptoms

Who should be cautious

  • Diabetes, prediabetes, metabolic syndrome, or strong family history (glucose tolerance concern)
  • Heart failure / edema-prone conditions
  • Pregnant or breastfeeding individuals
  • Adolescents (growth/endocrine setpoints; not an appropriate context)

Interactions summarize known or plausible ways this peptide may intersect with medications, supplements, or physiologic states. Use this as a risk-awareness map: what to ask about, what to watch for, and what deserves a clinician conversation.

Medication classes
Endocrine Axis Modulation Context
Supplement classes
None
Other peptides
None
Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.
No curated human clinical sources have been added yet.
Status reflects how MK-677 appears in clinical literature and/or real-world contexts. This is descriptive only. Classification describes what MK-677 is and the general domain where it appears.
Pep-Talk is informational only and not medical advice. We make no warranties and are not liable for actions you take. You are responsible for your decisions and outcomes.

Community notes

Educational discussion only. No dosing, protocols, schedules, or instructions. Submissions are moderated before appearing.
Loading…
Submit a note